BioNxt Launches Feasibility Study for Oral Dissolvable Film Semaglutide Delivery

BioNxt Solutions Inc. (搜索)搜索该词条 has announced the launch of a feasibility study to develop an oral dissolvable film (ODF) formulation of Semaglutide查看药品详情, marking a significant exploration into alternative delivery methods for the blockbuster GLP-1 receptor (搜索)搜索该靶点 agonist currently marketed under brand names Ozempic查看药品详情®, Rybelsus查看药品详情®, and Wegovy查看药品详情®.

The initiative represents a strategic evaluation of BioNxt's proprietary thin film drug delivery platform as a non-invasive, user-friendly alternative to existing injectable and tablet-based GLP-1 therapies. The study is designed to assess the compatibility of Semaglutide查看药品详情 with BioNxt's ODF technology and generate early data to inform formulation optimization and intellectual property strategy.

Market Opportunity and Current Limitations

Semaglutide查看药品详情 has rapidly emerged as a blockbuster drug for type 2 diabetes (搜索)搜索该疾病 and obesity (搜索)搜索该疾病, with growing applications in cardiovascular risk reduction. According to a 2024 report by Data Bridge Market Research, the global GLP-1 receptor (搜索)搜索该靶点 agonist market was valued at $24.4 billion in 2023 and is projected to reach approximately $156.7 billion by 2030, driven by increasing obesity rates and the rising demand for non-insulin therapies.

Despite its clinical success, current Semaglutide查看药品详情 formulations present adherence challenges. Most formulations still require weekly injections or large daily oral tablets, which can affect patient compliance. A rapidly dissolving oral thin film promises to address these limitations by offering improved accessibility, convenience, and overall patient experience.

"We believe there is a compelling opportunity to rethink how complex molecules like Semaglutide查看药品详情 are delivered," said Hugh Rogers, CEO at BioNxt. "Our oral thin film platform is engineered to improve patient adherence and comfort, and this feasibility study is an important first step in bringing a new delivery option to market."

Study Design and Timeline

The feasibility program encompasses several key components, including pre-formulation screening and platform compatibility assessment, drug loading and film integrity evaluation for peptide stability, and generation of early-stage technical data to support patent filings.

The feasibility study is currently in the planning phase, with receipt of the Semaglutide查看药品详情 active pharmaceutical ingredient (API) anticipated in July. Upon delivery, pre-formulation activities and laboratory-scale formulation trials will be initiated. Subsequent prototype development and characterization are expected to support a provisional patent filing in the third quarter of 2025.

Platform Expansion Strategy

This project represents a strategic expansion of BioNxt's oral thin film drug delivery platform, which is designed to enable the non-invasive administration of high-value therapeutics. Semaglutide查看药品详情 is the first in a planned series of GLP-1 receptor (搜索)搜索该靶点 agonists being developed using this technology.

The platform is particularly well-suited for peptide-based compounds and holds significant potential to support additional thin film solutions across the rapidly growing class of GLP-1 therapies targeting diabetes, obesity (搜索)搜索该疾病, and related metabolic disorders. BioNxt's proprietary platforms include Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets) technologies targeting key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity applications.